全文获取类型
| 收费全文 | 144篇 |
| 免费 | 9篇 |
专业分类
| 耳鼻咽喉 | 3篇 |
| 儿科学 | 2篇 |
| 妇产科学 | 2篇 |
| 基础医学 | 13篇 |
| 口腔科学 | 13篇 |
| 临床医学 | 19篇 |
| 内科学 | 22篇 |
| 皮肤病学 | 1篇 |
| 神经病学 | 7篇 |
| 特种医学 | 7篇 |
| 外科学 | 22篇 |
| 综合类 | 8篇 |
| 预防医学 | 11篇 |
| 药学 | 7篇 |
| 中国医学 | 10篇 |
| 肿瘤学 | 6篇 |
出版年
| 2024年 | 1篇 |
| 2023年 | 5篇 |
| 2022年 | 22篇 |
| 2021年 | 4篇 |
| 2020年 | 9篇 |
| 2019年 | 26篇 |
| 2018年 | 28篇 |
| 2017年 | 19篇 |
| 2016年 | 6篇 |
| 2015年 | 5篇 |
| 2014年 | 13篇 |
| 2013年 | 9篇 |
| 2012年 | 2篇 |
| 2011年 | 2篇 |
| 2009年 | 1篇 |
| 2006年 | 1篇 |
排序方式： 共有153条查询结果，搜索用时 15 毫秒
1.
2.
Background/Objectives
Due to its rarity, epidermoid cyst in intrapancreatic accessory spleen (ECIPAS) is still a diagnostic dilemma during clinical practice. The aim of this review was to summarize the epidemiologic features and management of ECIPAS.Methods
MEDLINE and EMBASE were searched for English articles reporting on ECIPAS up to April 30th, 2018 following the methodology suggested by the PRISMA guidelines. Categorical variables were reported as frequency and percentage. Continuous variables were reported as median (range).Results
A total of 56 patients from 47 full articles were included for the final data synthesis. More than half of the ECIPASs (59%) were found incidentally. The female/male ratio was 1.33. ECIPAS is typically a single mono-/multi-lobular cystic lesions in the pancreatic tail with thickened cystic wall or various amount of solid component which had identical density/signal to the spleen on imaging examinations. The cyst is filled with serous or non-serous fluid. Recognition of the surrounding ectopic splenic tissue is the key point to diagnose ECIPAS. However, no preoperative examination was able to make a definite diagnosis. Almost all the patients (96%) received surgical treatment, due to the suspicion of pancreatic malignant or potentially malignant cystic tumor, especially mucinous cystic neoplasm (MCN).Conclusions
Although seldom encountered, ECIPAS should be considered as a differential diagnosis for pancreatic cystic lesions, especially when solid component was detected. As a benign disease, unnecessary surgery should be avoided. Because it is difficult to make a definite diagnosis preoperatively by one single examination, multiple modalities may be required. 相似文献3.
Y.K. Cho Y.M. Kang S.E. Lee J. Lee J.-Y. Park W.J. Lee Y.-J. Kim C.H. Jung 《Diabetes & metabolism》2018,44(5):393-401
Background
This review evaluated the efficacy and safety of a combination therapy comprising a sodium-glucose cotransporter type 2 inhibitor (SGLT2i) and dipeptidyl peptidase-4 inhibitor (DPP4i) in type 2 diabetes.Methods
A literature search through to May 2017 was carried out of PubMed, Embase and the Cochrane Central Register of Controlled Trials. Studies were eligible if they were randomized controlled trials (RCTs) comparing SGLT2i plus DPP4i (SGLT2i/DPP4i) against DPP4i ± placebo or SGLT2i ± placebo and published in English. The primary outcome was change in HbA1c from baseline.Results
Eight RCTs comparing SGLT2i/DPP4i and DPP4i, and five RCTs comparing SGLT2i/DPP4i and SGLT2i, with three RCTs involving both comparisons, were included in the present review. SGLT2i/DPP4i resulted in a greater mean HbA1c reduction [weighted mean difference (WMD]): ?0.62%] than did DPP4i alone, which was a much less marked reduction (WMD: ?0.35%) than with SGLT2i alone. Also, significant differences in body weight loss from baseline were observed only with SGLT2i/DPP4i vs. DPP4i, but not vs. SGLT2i. The risk of hypoglycaemic events was low and similar between treatment groups. When subjects were stratified based on baseline HbA1c, any reduction by SGLT2i/DPP4i in relation to DPP4i was proportional to baseline HbA1c levels. However, compared with SGLT2i, HbA1c reductions with SGLT2i/DPP4i were modest regardless of baseline HbA1c.Conclusion
Combination therapy with SGLT2i and DPP4i is both efficacious and safe. In particular, a marked additional glucose-lowering effect is evident when SGLT2i is combined with or added to DPP4i, and not vice versa. However, baseline HbA1c determined the additional glucose-lowering effects of SGLT2i in combined treatment with DPP4i. 相似文献4.
5.
2015年,单个病例数据系统评价/Meta分析优先报告条目(Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data, PRISMA-IPD)声明的推出对单个病例数据系统评价/Meta 分析(Systematic reviews and Meta-Analyses of Individual Patient Data)的规范报告将会发挥重要的作用。本文旨在对PRISMA-IPD声明形成的背景、过程及其内容和要求进行介绍。 相似文献
6.
A great effort has been made to identify crucial cognitive markers that can be used to characterize the cognitive profile of Alzheimer's disease (AD). Because topographical disorientation is one of the earliest clinical manifestation of AD, an increasing number of studies have investigated the spatial deficits in this clinical population. In this systematic review, we specifically focused on experimental studies investigating allocentric and egocentric deficits to understand which spatial cognitive processes are differentially impaired in the different stages of the disease. First, our results highlighted that spatial deficits appear in the earliest stages of the disease. Second, a need for a more ecological assessment of spatial functions will be presented. Third, our analysis suggested that a prevalence of allocentric impairment exists. Specifically, two selected studies underlined that a more specific impairment is found in the translation between the egocentric and allocentric representations. In this perspective, the implications for future research and neurorehabilitative interventions will be discussed. 相似文献
7.
Pyeong Hwa Kim Jiaywei Tsauo Ji Hoon Shin Sung-Cheol Yun 《Journal of vascular and interventional radiology : JVIR》2017,28(4):522-531.e5
Purpose
To evaluate the safety and efficacy of transcatheter arterial embolization with N-butyl cyanoacrylate (NBCA) for the treatment of gastrointestinal (GI) bleeding via a meta-analysis of published studies.Materials and Methods
The MEDLINE/PubMed and EMBASE databases were searched for English-language studies from January 1990 to March 2016 that included patients with nonvariceal GI bleeding treated with transcatheter arterial embolization with NBCA with or without other embolic agents. The exclusion criteria were a sample size of < 5, no extractable data, or data included in subsequent articles or duplicate reports.Results
The cases of 440 patients (mean age, 63.8 y ± 14.3; 319 men [72.5%] and 121 women [27.5%]) from 15 studies were evaluated. Of these patients, 261 (59.3%) had upper GI bleeding (UGIB) and 179 (40.7%) had lower GI bleeding (LGIB). Technical success was achieved in 99.2% of patients with UGIB (259 of 261) and 97.8% of those with LGIB (175 of 179). The pooled clinical success and major complication rates in the 259 patients with UGIB in whom technical success was achieved were 82.1% (95% confidence interval [CI], 73.0%–88.6%; P = 0.058; I2 = 42.7%) and 5.4% (95% CI, 2.8%–10.0%; P = 0.427; I2 = 0.0%), respectively, and those in the 175 patients with LGIB in whom technical success was achieved were 86.1% (95% CI, 79.9%–90.6%; P = 0.454; I2 = 0.0%) and 6.1% (95% CI, 3.1%–11.6%; P = 0.382; I2 = 4.4%), respectively.Conclusions
Transcatheter arterial embolization with NBCA is safe and effective for the treatment of GI bleeding. 相似文献8.
Jared Scott Benjamin Howard Philip Sinnett Michael Schiesel Jana Baker Patrick Henderson Matt Vassar 《The American journal of emergency medicine》2017,35(12):1828-1835
Background
The objective of this study was to assess the methodological quality and clarity of reporting of the systematic reviews (SRs) supporting clinical practice guideline (CPG) recommendations in the management of ST-elevation myocardial infarction (STEMI) across international CPGs.Methods
We searched 13 guideline clearinghouses including the National Guideline Clearinghouse and Guidelines International Network (GIN). To meet inclusion criteria CPGs must be pertinent to the management of STEMI, endorsed by a governing body or national organization, and written in English. We retrieved SRs from the reference sections using a combination of keywords and hand searching. Two investigators scored eligible SRs using AMSTAR and PRISMA.Results
We included four CPGs. We extracted 71 unique SRs. These SRs received AMSTAR scores ranging from 1 (low) to 9 (high) on an 11-point scale. All CPGs consistently underperformed in areas including disclosure of funding sources, risk of bias, and publication bias according to AMSTAR. PRISMA checklist completeness ranged from 44% to 96%. The PRISMA scores indicated that SRs did not provide a full search strategy, study protocol and registration, assessment of publication bias or report funding sources. Only one SR was referenced in all four CPGs. All CPGs omitted a large subset of available SRs cited by other guidelines.Conclusions
Our study demonstrates the variable quality of SRs used to establish recommendations within guidelines included in our sample. Although guideline developers have acknowledged this variability, it remains a significant finding that needs to be addressed further.Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 相似文献9.
Stefano Federici Marco Bracalenti Fabio Meloni Juan V. Luciano 《Disability and rehabilitation》2017,39(23):2347-2380
Purpose: This systematic review examines research and practical applications of the World Health Organization Disability Assessment Schedule (WHODAS 2.0) as a basis for establishing specific criteria for evaluating relevant international scientific literature. The aims were to establish the extent of international dissemination and use of WHODAS 2.0 and analyze psychometric research on its various translations and adaptations. In particular, we wanted to highlight which psychometric features have been investigated, focusing on the factor structure, reliability, and validity of this instrument.
Method: Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) methodology, we conducted a search for publications focused on “whodas” using the ProQuest, PubMed, and Google Scholar electronic databases.
Results: We identified 810 studies from 94 countries published between 1999 and 2015. WHODAS 2.0 has been translated into 47 languages and dialects and used in 27 areas of research (40% in psychiatry).
Conclusions: The growing number of studies indicates increasing interest in the WHODAS 2.0 for assessing individual functioning and disability in different settings and individual health conditions. The WHODAS 2.0 shows strong correlations with several other measures of activity limitations; probably due to the fact that it shares the same disability latent variable with them.
- Implications for Rehabilitation
WHODAS 2.0 seems to be a valid, reliable self-report instrument for the assessment of disability.
The increasing interest in use of the WHODAS 2.0 extends to rehabilitation and life sciences rather than being limited to psychiatry.
WHODAS 2.0 is suitable for assessing health status and disability in a variety of settings and populations.
A critical issue for rehabilitation is that a single “minimal clinically important .difference” score for the WHODAS 2.0 has not yet been established.
10.